Teva Pharmaceutical Industries Limited Targets Roche Holding AG's Rituxan in Biosimilar Drug Trial

Bloomberg -- Teva Pharmaceutical Industries Ltd. is testing a copy of Roche Holding AG’s second-biggest-selling drug Rituxan in what may be the first U.S. generic version of a monoclonal antibody, a protein-based medicine used to treat diseases ranging from arthritis to cancer.

Back to news